Biogen Inc. (NASDAQ: BIIB) reported its financial results for the quarter ended March 31, 2020 today.
Biogen posted a 1% decline in earnings for the first quarter of 2020 due to higher costs and expenses despite a 1% rise in the top-line. The company continued to develop and expand its pipeline, including making good progress toward the US regulatory filing for aducanumab, as well as bolstering its efforts in gene therapy through a collaboration with Sangamo.
The company believes that the magnitude and uncertainty surrounding the COVID-19 pandemic clearly introduce unanticipated and potentially unquantifiable risks to its business and results over the near-term. While Biogen does expect there will be some impact on timelines for certain of its clinical programs, it still expects the vast majority of the 10 remaining near-term readouts to occur before the end of 2021.
Past Performance
Most Popular
Docusign (DOCU) Earnings: 4Q25 Key Numbers
Docusign, Inc. (NASDAQ: DOCU) reported total revenue of $776.3 million for the fourth quarter of 2025, up 9% year-over-year. Net income was $83.5 million, or $0.39 per share, compared to
DG Q4 Call Highlights: Consumer Shifts, Inventory Wins, and Rural Delivery Boom!
Dollar General Corp., a retailer that operates discount stores, in its Q4 earnings call discussed Dollar General's financial strategy to reach 6-7% operating margins by 2028 through shrink reduction, inventory
ULTA Earnings: Highlights of Ulta Beauty’s Q4 2024 results
Ulta Beauty, Inc. (NASDAQ: ULTA), a leading retailer of cosmetics and personal care products, on Thursday reported a decrease in net sales for the fourth quarter of 2024. Fourth-quarter net
